Design Therapeutics (DSGN) EBIT (2020 - 2026)
Design Therapeutics recorded quarterly EBIT of -$19.7 million in Q1 2026, down 8.46% quarter-over-quarter from -$18.2 million in Q4 2025, and up 3.49% year-over-year from -$19.0 million in Q1 2025.
Design Therapeutics' EBIT history runs 7 years deep, the most recent figure standing at -$19.7 million for Q1 2026.
- In Q1 2026, EBIT rose 3.49% year-over-year to -$19.7 million; the TTM figure through Mar 2026 stood at -$78.8 million (down 15.14% YoY), while the FY2025 annual figure was -$79.5 million, down 27.39% from the prior year.
- EBIT came in at -$19.7 million for Q1 2026 at Design Therapeutics, down from -$18.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$13.4 million in Q1 2022 to a low of -$22.6 million in Q2 2023.
- A 5-year average of -$18.1 million and a median of -$18.8 million in 2023 frame the typical range for EBIT.
- Across the five-year window, EBIT plunged 135.39% in 2022 and surged 33.49% in 2024, its largest moves.
- Design Therapeutics' EBIT stood at -$19.4 million in 2022, then grew by 22.02% to -$15.1 million in 2023, then retreated by 10.4% to -$16.7 million in 2024, then fell by 8.84% to -$18.2 million in 2025, then fell by 8.46% to -$19.7 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$19.7 million, -$18.2 million, and -$19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -19.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.71 Mn |
| Dec 31, 2025 | -18.17 Mn |
| Sep 30, 2025 | -19.31 Mn |
| Jun 30, 2025 | -21.57 Mn |
| Mar 31, 2025 | -20.42 Mn |
| Dec 31, 2024 | -16.69 Mn |
| Sep 30, 2024 | -16.25 Mn |
| Jun 30, 2024 | -15.04 Mn |
| Mar 31, 2024 | -14.40 Mn |
| Dec 31, 2023 | -15.12 Mn |
| Sep 30, 2023 | -18.82 Mn |
| Jun 30, 2023 | -22.60 Mn |
| Mar 31, 2023 | -21.65 Mn |
| Dec 31, 2022 | -19.39 Mn |
| Sep 30, 2022 | -19.19 Mn |
| Jun 30, 2022 | -15.64 Mn |
| Mar 31, 2022 | -13.37 Mn |
| Dec 31, 2021 | -11.13 Mn |
| Sep 30, 2021 | -11.34 Mn |
| Jun 30, 2021 | -7.69 Mn |
| Mar 31, 2021 | -5.68 Mn |
| Dec 31, 2020 | -3.86 Mn |
| Sep 30, 2020 | -2.38 Mn |
| Jun 30, 2020 | -1.46 Mn |
| Mar 31, 2020 | -623,000.00 |